BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) concerning the Company and its officers’ possible violations of federal securities laws.
The investigation concerns whether the Company misled investors regarding the FDA’s inquiry into whether data from the Spectrum 611 and 612 Studies were clinically meaningful; and whether the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies. Following the Company’s announcement that the FDA had denied approval for its apaziquone NDA the Company’s shares fell sharply in value.
If you purchased Spectrum securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.